Binding Site technology to be used in myeloma research project

Binding Site has been chosen as a key diagnostic partner for the Black Swan Research Initiative, a project that aims to find a new cure for multiple myeloma.

Sponsored by the International Myeloma Foundation, the international collaboration will see an elite team of experts working to find a fresh treatment approach for the disease, having already identified the tools they plan to use.

Binding Site's Freelite and Hevylite blood test technologies were among those chosen by the expert panel. They are used worldwide to aid understanding of the course of myeloma cases and to gauge how patients are responding to treatment.

Together, these tests have been the subject of more than 2,500 peer reviewed papers, and both are approved for use in the EU and US, with Hevylite receiving the green light for international patent applications earlier this year.

Dr Stephen Harding, research and development director at Binding Site, said: "We have a total commitment to research in this field and Binding Site is delighted to support this IMF initiative aimed at improving patient outcomes."